News

Thermo Fisher Scientific TMO recently announced the opening of its first electron microscopy demo center in Taiwan. This state-of-the-art facility, named NanoPort, is strategically located in the region’s semiconductor manufacturing hub and designed to meet the area’s growing need for advanced analytical instruments and expertise.

With this latest addition in Taiwan, TMO aims to become the go-to R&D partner in the region. The company is committed to the expansion of science and technology worldwide.

More on the News

The new center in Taiwan will be one of the six Thermo Fisher NanoPort facilities worldwide. It will also partner with the semiconductor customers in the region.

The opening ceremony will take place on Jul 26, 2024.

The new NanoPort will give customers access to Thermo Fisher’s electron microscopy experts and its latest technologies for materials analysis, process control and quality assurance. Such accessibility is designed to support fundamental research efforts and offer hands-on experiences to help customers learn new ways to reduce time-to-market and ultimately increase profitability.

Market Prospect

Per a Market Research Future report, the Electron Microscope market was valued at $4.66 billion in 2023 and is expected to grow from $5.13 billion in 2024 to $10.22 billion by 2032 at a CAGR of 8.0%. Primary factors influencing market growth include the rising need for research based on nanotechnology and the ensuing increase in financing. Additionally, the market is expected to be driven by expanding product applications in the semiconductor, electronics, and pharmaceutical industries.

Image Source: Zacks Investment Research

Looking at the market potential, the latest addition to the NanoPort facility in Taiwan is in favor of Thermo Fisher.

Other Notable Developments

In June 2024, Thermo Fisher had several developments, including the introduction of biobased films to help reduce climate impact on the manufacturing of therapies. It also unveiled the Thermo Scientific Stellar mass spectrometer, which combines fast throughput, high sensitivity, and ease of use to allow researchers to advance their translational omics research and make breakthrough discoveries more efficiently.

Additionally, the company opened a new clinical and commercial ultra-cold facility in the European Union (EU), expanding its clinical trial network in Europe to help accelerate the development of advanced therapies.

In May 2024, TMO launched the Applied Biosystems Axiom BloodGenomiX Array and Software, which is a first-of-its-kind solution for more precise blood genotyping in clinical research.

Price Performance

Year to date, TMO’s shares have risen 0.2% compared with the industry’s 3.2% growth.

Zacks Rank and Other Key Picks

Thermo Fisher currently carries a Zacks Rank #2 (Buy).

Some other top-ranked stocks in the broader medical space are Hims & Hers Health, Inc. HIMS, Medpace Holdings MEDP and Haemonetics HAE. While Hims & Hers Health and Haemonetics currently sport a Zacks Rank #1 (Strong Buy) each, Medpace carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Hims & Hers Heath stock has surged 140.3% in the past year. Estimates for the company’s 2024 earnings have moved north 10% to 20 cents per share in the past 30 days.

HIMS’ earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. In the last reported quarter, it posted an earnings surprise of a staggering 150%.

Estimates for Medpace’s 2024 EPS have remained unchanged at $11.29 in the past 30 days. Shares of the company have soared 69.9% in the past year compared with the industry’s 4.3% growth.

MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.8%. In the last reported quarter, it delivered an earnings surprise of 30.6%.

Estimates for Haemonetics’ 2024 EPS have increased 0.4% to $4.57 in the past 30 days. In the past year, shares of HAE have lost 1.3% compared with the industry’s 3.2% decline.

In the last reported quarter, HAE delivered an earnings surprise of 2.27%. It has a trailing four-quarter average earnings surprise of 13.24%.

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report

Haemonetics Corporation (HAE) : Free Stock Analysis Report

Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report

Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.